

At the pulse of heart diseases

Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior's therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunction. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide.

Key facts



Founded 2016 and located in Hanover, Germany



Addressing cardiac diseases with ncRNAs



Broad proprietary platform



Series A: € 15M
Series B: € 64M




Lead candidate with blockbuster potential




Experienced management team


Technology



Diseased cardiac tissue



Cardior's treatment



Cardiac tissue normalization

Cardior's strong foundation for growth and innovation is based on non-coding RNAs (ncRNAs) that orchestrate fundamental cellular cardiac processes.

Targeting ncRNAs by Cardior's innovative therapeutics serve as a disease curating approach by triggering a concerted therapeutic effect against key hallmarks of heart disease, including cardiac remodeling processes such as pathological hypertrophy, impaired contractility and fibrosis.

From the company's growing pipeline of product compounds, the lead candidate demonstrates safety, tolerability, strong target engagement, initial efficacy and is currently being evaluated in a Phase 2 clinical trial in heart failure patients (NCT05350969).



Signaling pathways



RNA



RNA bound by Cardior's oligonucleotide

Key Publications



Pipeline

Program	Indication	MoA	Development Stage
CDR132L	Post-Myocardial Infarction (MI) Heart Failure	Interaction with miR-132	DISCOVERY, PRECLINICAL, SAFETY/TOX, PHASE1, PHASE2
CDR132L	Heart Failure with Preserved Ejection Fraction	Interaction with miR-132	DISCOVERY, PRECLINICAL, SAFETY/TOX, PHASE1
CDR132L	Dilated Cardiomyopathy	Interaction with miR-132	DISCOVERY, PRECLINICAL, SAFETY/TOX
CDR348T	Hypertrophic Cardiomyopathy	Modulation of ncRNAs	DISCOVERY, PRECLINICAL
CDR641L	Hypertrophic Cardiomyopathy	Interaction with ncRNA	DISCOVERY
Undisclosed	Diverse Indications	Interaction with ncRNAs	DISCOVERY, PRECLINICAL, SAFETY/TOX

Our lead candidate CDR132L is an inhibitor directed against miRNA132, designed to halt and reverse the development of detrimental cardiac remodeling. As a therapeutic candidate, CDR132L has several distinguishing features:

- **CDR132L** selectively blocks aberrant miRNA132 levels contributing to improved cardiac systolic and diastolic function in patients
- **CDR132L** has the potential to prolong the patient's life span as well as improve quality of life
- **CDR132L** is a highly stable watersoluble oligonucleotide formulated for parenteral or subcutaneous application

The advantages of the Cardior platform



Based on world-leading expertise in the therapeutic modulation of RNAs through synthetic oligonucleotides



Highly stable and effective RNA therapies resulting from a proprietary discovery engine



Pre-clinical proof-of-concept demonstrating the potential of the approach and first clinical evaluation completed



Deep understanding of the complex interplay of multiple disease-causing mechanisms and the role of ncRNAs



Effective target modulation and targeted delivery into the heart achieved



Successful scale up of a fast and cost-efficient GMP grade manufacturing

Leadership Team

Claudia Ulbrich, MD
CEO & Co-Founder

Prof. Thomas Thum, MD
CSO/CMO & Founder

Axel-Sven Malkomes
CFO

Steffen Rump, PhD
VP Operations

Peter Ruile, PhD
VP Business Development
& Licensing

Board

Claus Andersson
PhD

Simone Botti
PhD

Christoph Broja
CFA

Leon Carayannopoulos
MD, PhD

Halina Novak
PhD

Ulrich Granzer
PhD

Russell Greig
PhD, Chairman

Markus Hosang
PhD, Vice-chairman

Orly Vardeny
PharmD, Permanent Guest

Scientific Advisory Board

Prof. Johann Bauersachs
MD

Prof. Javed Butler
MD

Prof. Perry Elliott
MD

Gerasimos Filippatos
MD, PhD

Arthur A. Levin
PhD

Prof. Scott Solomon
MD

Barry Ticho
MD, PhD

Prof. Faiez Zannad
MD, PhD

Investors

BioMed  **Partners**

 **Bristol Myers Squibb**

COPARION

IEQT

 **Fund+**
Impacting Life Sciences

 **High-Tech Gründerfonds**

 **HADEAN**
VENTURES

Inkef

sunstone
LIFE SCIENCE VENTURES

Cardior Pharmaceuticals GmbH
Hollerithallee 20
30419 Hannover

Email
info@cardior.de

Phone
+49 511 3385 9930

Find us on social media

